Bryan S. Yung

676 Lymphatic-sparing immunoradiotherapy reprograms migratory dendritic cells to drive tumor rejection via the sentinel lymph node

Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Sayed Sadat et autres

Background The phase III trial KEYNOTE-689 has now established a new standard of care in resectable, locally advanced head and neck squamous cell carcinoma by integrating perioperative PD-1 blockade with surgery and (chemo)radiation. In contrast, four recent phase III trials adding concurrent …

us (code pays fourni par la source)

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Ming Cheng et autres

The most effective treatments for locally advanced cancers rely on non-targeted chemotherapies given with radiotherapy. Advances in cancer biology have identified vulnerabilities amenable to precision oncology approaches including antibody drug conjugates (ADCs). In theory, ADCs combine specificity of cancer cell receptor antibody …

us (code pays fourni par la source)

The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy

Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Sayed Sadat et autres

Surgical ablation or broad radiation of tumor-draining lymph nodes can eliminate the primary tumor response to immunotherapy, highlighting the crucial role of these nodes in mediating the primary tumor response. Here, we show that immunoradiotherapy efficacy is dependent on treatment sequence and …

us (code pays fourni par la source)

Abstract 3764: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy

Robert Saddawi‐Konefka, Riyam Al Msari, Cynthia Y. Tang, Sayed Sadat et autres

Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. We previously demonstrated that ablating tumor draining lymphatics abolishes the response to immune-oncology therapy. Specifically, …

us (code pays fourni par la source)

Antigenic cancer persister cells survive direct T cell attack

Michael Wang, Brandon E. Mauch, August F. Williams, Tania Barazande-Pour et autres

Summary Drug-tolerant persister cancer cells were first reported fifteen years ago as a quiescent, reversible cell state which tolerates unattenuated cytotoxic drug stress. It remains unknown whether a similar phenomenon contributes to immune evasion. Here we report a persister state which survives …

us (code pays fourni par la source)

Abstract B019: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy

Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Lauren M. Clubb et autres

Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. To address this hypothesis, we previously demonstrated that ablating tumor draining lymphatics abolishes the response …

us (code pays fourni par la source)

Abstract P004: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy

Robert Saddawi‐Konefka, Riyam Al Msari, Shiqi Tang, Lauren M. Clubb et autres

Abstract Immune checkpoint inhibition has demonstrated no benefit when combined with chemoradiotherapy for locally advanced HNSCC, raising the possibility that standard therapies compromise the response to immunotherapy. To address this hypothesis, we previously demonstrated that ablating tumor draining lymphatics abolishes the response …

us (code pays fourni par la source)

The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure

Victoria H. Wu, Bryan S. Yung, Farhoud Faraji, Robert Saddawi‐Konefka et autres

us, it (code pays fourni par la source)

Abstract 2868: A chemogenetic approach reveals a GPCR-Gαs-PKA signaling axis promoting T cell dysfunction and cancer immunotherapy failure

Bryan S. Yung, Victoria H. Wu, Farhoud Faraji, Robert Saddawi‐Konefka et autres

Abstract Recent advances in immune checkpoint blockade (ICB) inhibiting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein (CTLA-4) have revolutionized the standard of care for cancer treatment. However, the limited response rates to ICB across multiple cancer types suggest that new approaches and …

us, it (code pays fourni par la source)

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

Robert Saddawi‐Konefka, Aoife O’Farrell, Farhoud Faraji, Lauren M. Clubb et autres

Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain limited. This raises the possibility that standard of care treatments delivered in concert may compromise the tumor response. To address this, we employ tobacco-signature head and neck squamous cell carcinoma murine …

us (code pays fourni par la source)

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

Jorge Silvio Gutkind, Robert Saddawi‐Konefka, Aoife O’Farrell, Farhoud Faraji et autres

Abstract Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain limited. This raises the possibility that standard of care treatments delivered in concert may compromise the tumor response. To address this, we employed tobacco-signature HNSCC murine models in which we …

us, do (code pays fourni par la source)

Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC

Robert Saddawi‐Konefka, Aoife O’Farrell, Farhoud Faraji, Lauren M. Clubb et autres

Abstract Immune checkpoint inhibition (ICI) with anti-CTLA-4 and anti-PD-1 has revolutionized oncology; however, response rates remain limited in most cancer types, highlighting the need for more effective immune oncology (IO) treatment strategies. Paradoxically, head and neck squamous cell carcinoma (HNSCC), which bears …

us (code pays fourni par la source)